Cyramza and Colitis - a phase IV clinical study of FDA data

Summary:

Colitis is reported as a side effect among people who take Cyramza (ramucirumab), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Ondansetron, and have Gastric cancer.

The phase IV clinical study analyzes which people have Colitis when taking Cyramza. It is created by eHealthMe based on reports of 4,051 people who have side effects when taking Cyramza from the FDA, and is updated regularly.

What is Cyramza?

Cyramza has active ingredients of ramucirumab. eHealthMe is studying from 4,052 Cyramza users. Check the latest studies of Cyramza.

What is Colitis?

Colitis (inflammation of colon) is found to be associated with 1,597 drugs and 1,523 conditions by eHealthMe. Check the latest studies of Colitis.

On Jul, 15, 2026

4,051 people reported to have side effects when taking Cyramza.
Among them, 16 people (0.39%) have Colitis.

Among these 16 people:

How long have people been on Cyramza when they have Colitis? *

What is the gender of people who have Colitis when taking Cyramza? *

female: 14.29 %
male: 85.71 %

What is the age of people who have Colitis when taking Cyramza? *

What are other drugs people take besides Cyramza? *

What are other side effects people have besides Colitis? *

Large Intestine Perforation (hole in large intestine): 5 people, 31.25%
Malignant Neoplasm Progression (cancer tumour came back): 3 people, 18.75%
Death: 3 people, 18.75%
Diarrhea: 3 people, 18.75%
Stomatitis (inflammation of mucous membrane of mouth): 2 people, 12.50%
Septic Shock (shock due to blood infection): 2 people, 12.50%
Chest Pain: 2 people, 12.50%
Tongue Haemorrhage (bleeding from tongue): 1 person, 6.25%
Gastritis (inflammation of stomach): 1 person, 6.25%
Abdominal Pain Upper: 1 person, 6.25%

What are the existing conditions these people have? *

Oesophageal Squamous Cell Carcinoma (cancer that begins in flat cells lining the oesophagus): 3 people, 18.75%
Gastric Cancer (stomach cancer): 3 people, 18.75%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 2 people, 12.50%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 2 people, 12.50%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 12.50%
Oesophageal Carcinoma (cancer tumour of oesophagus): 1 person, 6.25%
Metastases To Lung (cancer spreads to lung): 1 person, 6.25%
Metastases To Liver (cancer spreads to liver): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Cyramza and have Colitis?

- Check whether Colitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cyramza:

Cyramza (4,052 reports)

Colitis treatments and more:

Colitis (53,790 reports)

Browse all side effects of Cyramza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Colitis:

Colitis (1,597 drugs)

Browse all the conditions that are associated with Colitis:

Colitis (1,523 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ramucirumab (the active ingredients of Cyramza) and Cyramza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.